| pubmed-article:16734731 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16734731 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16734731 | lifeskim:mentions | umls-concept:C0853879 | lld:lifeskim |
| pubmed-article:16734731 | lifeskim:mentions | umls-concept:C0035696 | lld:lifeskim |
| pubmed-article:16734731 | lifeskim:mentions | umls-concept:C0041538 | lld:lifeskim |
| pubmed-article:16734731 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
| pubmed-article:16734731 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:16734731 | lifeskim:mentions | umls-concept:C0681842 | lld:lifeskim |
| pubmed-article:16734731 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:16734731 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:16734731 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:16734731 | pubmed:dateCreated | 2006-5-31 | lld:pubmed |
| pubmed-article:16734731 | pubmed:abstractText | The present study investigated the mRNA expression level of ubiquitin c-terminal hydrolase (UCH)-L1 and -L3 in breast cancer tissue and aimed to elucidate its association with tumor characteristics and patient prognosis. UCH-L1 and UCH-L3 mRNA levels in invasive breast cancer (n = 100) were determined by a real-time polymerase chain reaction (PCR) assay and their relationship with various clinicopathological characteristics of breast tumors as well as patient prognosis were studied. UCH-L3 mRNA level was significantly upregulated in breast cancer tissue compared to adjacent normal breast tissue (P < 0.005), and UHC-L1 mRNA level also showed a non-significant increase in tumor tissue compared to adjacent normal breast tissue. Both UCH-L1 and UCH-L3 mRNA levels were significantly higher in high histological grade tumors than in low histological grade tumors (P < 0.001 and P < 0.005, respectively). High UCH-L1 mRNA level was significantly associated with negative estrogen receptor status (P < 0.05) and negative progesterone receptor status (P < 0.05). Patients with both UCH-L1 and UCH-L3 mRNA high tumors showed a significantly poorer prognosis than those in the UCH-L1 or UCH-L3 mRNA low group (P < 0.005). These observations that UCH-L3 mRNA level is upregulated in breast cancer tissue, and breast tumors with both UCH-L1 and UCH-L3 mRNA high expression are associated with a poor prognosis, suggest the possible involvement of UCH-L1 and UCH-L3 in the pathogenesis and progression of breast cancer. | lld:pubmed |
| pubmed-article:16734731 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16734731 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16734731 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16734731 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16734731 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16734731 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16734731 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16734731 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16734731 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16734731 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16734731 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:16734731 | pubmed:issn | 1347-9032 | lld:pubmed |
| pubmed-article:16734731 | pubmed:author | pubmed-author:MiyoshiYasuoY | lld:pubmed |
| pubmed-article:16734731 | pubmed:author | pubmed-author:TaguchiTetsuy... | lld:pubmed |
| pubmed-article:16734731 | pubmed:author | pubmed-author:TamakiYasuhir... | lld:pubmed |
| pubmed-article:16734731 | pubmed:author | pubmed-author:NoguchiShinza... | lld:pubmed |
| pubmed-article:16734731 | pubmed:author | pubmed-author:NakayamaSatos... | lld:pubmed |
| pubmed-article:16734731 | pubmed:author | pubmed-author:TanakaSatoshi... | lld:pubmed |
| pubmed-article:16734731 | pubmed:author | pubmed-author:IshiharaHidek... | lld:pubmed |
| pubmed-article:16734731 | pubmed:author | pubmed-author:TorikoshiYasu... | lld:pubmed |
| pubmed-article:16734731 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16734731 | pubmed:volume | 97 | lld:pubmed |
| pubmed-article:16734731 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16734731 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16734731 | pubmed:pagination | 523-9 | lld:pubmed |
| pubmed-article:16734731 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16734731 | pubmed:meshHeading | pubmed-meshheading:16734731... | lld:pubmed |
| pubmed-article:16734731 | pubmed:meshHeading | pubmed-meshheading:16734731... | lld:pubmed |
| pubmed-article:16734731 | pubmed:meshHeading | pubmed-meshheading:16734731... | lld:pubmed |
| pubmed-article:16734731 | pubmed:meshHeading | pubmed-meshheading:16734731... | lld:pubmed |
| pubmed-article:16734731 | pubmed:meshHeading | pubmed-meshheading:16734731... | lld:pubmed |
| pubmed-article:16734731 | pubmed:meshHeading | pubmed-meshheading:16734731... | lld:pubmed |
| pubmed-article:16734731 | pubmed:meshHeading | pubmed-meshheading:16734731... | lld:pubmed |
| pubmed-article:16734731 | pubmed:meshHeading | pubmed-meshheading:16734731... | lld:pubmed |
| pubmed-article:16734731 | pubmed:meshHeading | pubmed-meshheading:16734731... | lld:pubmed |
| pubmed-article:16734731 | pubmed:meshHeading | pubmed-meshheading:16734731... | lld:pubmed |
| pubmed-article:16734731 | pubmed:meshHeading | pubmed-meshheading:16734731... | lld:pubmed |
| pubmed-article:16734731 | pubmed:meshHeading | pubmed-meshheading:16734731... | lld:pubmed |
| pubmed-article:16734731 | pubmed:meshHeading | pubmed-meshheading:16734731... | lld:pubmed |
| pubmed-article:16734731 | pubmed:meshHeading | pubmed-meshheading:16734731... | lld:pubmed |
| pubmed-article:16734731 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16734731 | pubmed:articleTitle | High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. | lld:pubmed |
| pubmed-article:16734731 | pubmed:affiliation | Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. | lld:pubmed |
| pubmed-article:16734731 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16734731 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:16734731 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16734731 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16734731 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16734731 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16734731 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16734731 | lld:pubmed |
